CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $241.33M, lower than 95% of all stocks globally
- PositionReturn on equity is 21.8%, higher than 95% of its Biotechnology peers (median -23.3%)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
241.33MUSDvs all stocks (USD)
Trailing P/E
16.05xvs Biotechnology peers
Revenue (TTM)
129.08MUSDvs all stocks (USD)
Profit Margin
12.39%vs Biotechnology peers
Beta
2.09xvs all stocks
52-Week Change
-69.19%vs all stocks
Market Capitalization
241.33MUSDvs all stocks (USD)
Enterprise Value
177.58MUSDvs all stocks (USD)
Trailing P/E
16.05xvs Biotechnology peers
Forward P/E
30.50xvs Biotechnology peers
PEG Ratio
-0.2007xvs Biotechnology peers
Price to Sales (TTM)
1.87xvs Biotechnology peers
Price to Book (MRQ)
2.92xvs Biotechnology peers
Enterprise to Revenue
1.38xvs Biotechnology peers
Enterprise to EBITDA
18.52xvs Biotechnology peers
Gross Margin
64.84%vs Biotechnology peers
Profit Margin
12.39%vs Biotechnology peers
Operating Margin
2.35%vs Biotechnology peers
Return on Assets (TTM)
5.44%vs Biotechnology peers
Return on Equity (TTM)
21.80%vs Biotechnology peers
Revenue (TTM)
129.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.62USDUpdated Sep 28, 2026Quarterly Revenue Growth
-4.30%vs Biotechnology peers
Gross Profit (TTM)
82.92MUSDvs all stocks (USD)
EBITDA (TTM)
13.76MUSDvs all stocks (USD)
Net Income (TTM)
15.99MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-73.30%vs Biotechnology peers
Operating Cash Flow (TTM)
5.95MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
1.64MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
129.42MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
46.23MUSDFY2025 · Dec 31, 2025Gross Profit
83.19MUSDFY2025 · Dec 31, 2025Operating Income
14.30MUSDvs all stocks (USD)
Pre-tax Income
18.19MUSDFY2025 · Dec 31, 2025Income Tax Expense
810.00KUSDFY2025 · Dec 31, 2025Net Income
17.38MUSDFY2025 · Dec 31, 2025EBIT
14.30MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
13.76MUSDFY2025 · Dec 31, 2025Research & Development
6.33MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
62.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.13MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.2200USDFY2025 · Dec 31, 2025EPS (Diluted)
0.2000USDFY2025 · Dec 31, 2025Basic Shares Outstanding
79.18MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
79.18MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
17.38MUSDFY2025 · Dec 31, 2025Operating Cash Flow
11.76MUSDFY2025 · Dec 31, 2025Free Cash Flow
11.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
64.79MUSDFY2025 · Dec 31, 2025Interest Paid
1.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
17.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.45MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.07MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.95MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-756.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.71MUSDFY2025 · Dec 31, 2025Capital Expenditures
-292.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-292.00KUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-12.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-251.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-67.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-330.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
78.91MSharesUpdated Sep 28, 2026Float Shares
59.07MSharesUpdated Sep 28, 2026Shares Short
4.00MSharesUpdated Sep 28, 2026Short Ratio
9.52daysvs all stocks
Short % of Shares Outstanding
7.78%vs all stocks
% Held by Insiders
29.45%vs all stocks
% Held by Institutions
41.55%vs all stocks
Total Cash (MRQ)
66.59MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.8400USDUpdated Sep 28, 2026Total Debt (MRQ)
2.33MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0282xvs Biotechnology peers
Current Ratio (MRQ)
6.50xvs Biotechnology peers
Book Value per Share (MRQ)
1.04USDUpdated Sep 28, 2026Total Assets
106.41MUSDvs all stocks (USD)
Total Current Assets
96.81MUSDFY2025 · Dec 31, 2025Total Liabilities
29.87MUSDFY2025 · Dec 31, 2025Total Non-current Assets
9.60MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
9.95MUSDFY2025 · Dec 31, 2025Total Current Liabilities
19.92MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
64.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
9.74MUSDFY2025 · Dec 31, 2025Inventory
20.42MUSDFY2025 · Dec 31, 2025Accounts Payable
10.80MUSDFY2025 · Dec 31, 2025Short-term Debt
1.00MUSDFY2025 · Dec 31, 2025Deferred Revenue
399.00KUSDFY2025 · Dec 31, 2025Long-term Debt
1.81MUSDFY2025 · Dec 31, 2025Common Stock (Book)
79.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-164.53MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
76.53MUSDvs all stocks (USD)
52-Week Low
2.87USDUpdated Sep 28, 202652-Week High
10.06USDUpdated Sep 28, 202652-Week Change
-69.19%vs all stocks
Beta
2.09xvs all stocks
50-Day MA
3.16USDUpdated Sep 28, 2026200-Day MA
4.40USDUpdated Sep 28, 2026Avg 10-Day Volume
432.12KSharesUpdated Sep 28, 2026Avg 30-Day Volume
417.65KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.1900USDUpdated Sep 28, 2026Other Income / Expense
1.77MUSDFY2025 · Dec 31, 20256 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 21.8%, higher than 95% of its Biotechnology peers (median -23.3%)Significant
Return on equity: 0.22Industry median: -0.23Industry P95: 0.19Peers compared: 258
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 15,991,000Operating Cash Flow (USD, TTM): 5,949,000
Financial Health
Altman Z-Score 5.21: safe zoneNotable
Altman Z-Score: 5.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $241.33M, lower than 95% of all stocks globallySignificant
Market cap (USD): 241,334,306Global P5: 283,534,814
Companies that share the same coordination system — how they create, deliver, or capture value.
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunotech Biopharm Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Jiuyuan Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fischer Medical Ventures Ltd
Tier 1ProductionApproval-Gated PipelineFlowRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ies Holdings Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Medpace Holdings Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover
Nextracker Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthIndustry-Benchmarked Return on Capital ElevatedLow Fixed-Asset Share With Elevated Turnover